SREBF1 and hyperlipidemia: However, eightweeks of MO-A treatment up-regulated the expression levels of both LDLR andPPARα, and down-regulated the expression levels of both ACC and SREBP-1C(P<0.05 or P<0.01), indicating that MO-A ameliorated hyperlipidemia partlyby modulating the expression levels involved in lipogenesis and lipidoxidation.